We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Ra Pharmaceuticals, Inc. (“Ra Pharma” or the “Company”) (NASDAQ: RA) to UCB S.A. (“UCB”). Under the terms of the deal Ra Pharma shareholders will receive $48.00 in cash for each Ra Pharma share at closing.
The Ra Pharma merger investigation concerns whether the Board of Ra Pharma breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether UCB is underpaying for Ra Pharma shares, thus unlawfully harming Ra Pharma shareholders.
To receive more information, please fill out the form.